UBS Group’s Oasmia Pharmaceutical AB OASM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-2,723
| Closed | -$3K | – | 8545 |
|
|
2019
Q2 | $3K | Sell |
2,723
-901
| -25% | -$1.63K | ﹤0.01% | 7584 |
|
|
2019
Q1 | $8K | Sell |
3,624
-417
| -10% | -$1.14K | ﹤0.01% | 6983 |
|
|
2018
Q4 | $12K | Buy |
4,041
+1,286
| +47% | +$5.08K | ﹤0.01% | 7172 |
|
|
2018
Q3 | $12K | Buy |
2,755
+1,905
| +224% | +$3.99K | ﹤0.01% | 7091 |
|
|
2018
Q2 | $1K | Sell |
850
-1,723
| -67% | -$2.51K | ﹤0.01% | 7892 |
|
|
2018
Q1 | $3K | Buy |
2,573
+534
| +26% | +$700 | ﹤0.01% | 7482 |
|
|
2017
Q4 | $2K | Sell |
2,039
-1,602
| -44% | -$1.54K | ﹤0.01% | 7662 |
|
|
2017
Q3 | $4K | Sell |
3,641
-3,686
| -50% | -$3.81K | ﹤0.01% | 7351 |
|
|
2017
Q2 | $8K | Buy |
7,327
+7,217
| +6,561% | +$12.7K | ﹤0.01% | 6948 |
|
|
2017
Q1 | $0 | Buy |
+110
| New | +$258 | ﹤0.01% | 8200 |
|
|
2016
Q1 | – | Sell |
-1,900
| Closed | -$7K | – | 8482 |
|
|
2015
Q4 | $7K | Buy |
+1,900
| New | +$7.47K | ﹤0.01% | 7549 |
|
UBS Group's OASM Position: Q3 2019 in Review
UBS Group sold out of Oasmia Pharmaceutical AB (OASM) in Q3 2019, closing a stake of 2,723 shares — an estimated $3K sold.
UBS Group first reported a position in OASM in Q4 2015 and held it in 11 quarters. The position peaked at $12K in Q4 2018. 0 funds tracked by Wall St. Rank hold OASM as of Q3 2019.
- UBS Group reported no remaining Oasmia Pharmaceutical AB position as of Q3 2019 after selling out during the quarter.
- UBS Group sold 2,723 Oasmia Pharmaceutical AB shares in Q3 2019, an estimated $3K.
- UBS Group first reported a position in Oasmia Pharmaceutical AB in Q4 2015 and held it in 11 quarters.
- UBS Group's Oasmia Pharmaceutical AB position peaked at $12K in Q4 2018.
- 0 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q3 2019.
Based on UBS Group's 13F filing for Q3 2019, filed 14 Nov 2019.